Table 1.
Baseline Clinical Characteristics of Study Patients, Stratifed by Presence or Absence of Prior Acromegalya
| Prior acromegaly |
No prior acromegaly |
||||
|---|---|---|---|---|---|
| Factor | Placebo (n = 8) |
Growth hormone (n = 9) |
Placebo (n = 19) |
Growth hormone (n = 19 ) |
P value |
| Age (y) | 41 ± 7.5 | 44 ± 15 | 47 ± 7.9 | 44 ± 10 | .44 |
| Body mass index (kg/m2) | 29.9 ± 4.8 | 30.4 ± 2.9 | 29.0 ± 6.5 | 30.1 ± 7.7 | .96 |
| Growth hormone peak (ng/mL) | 3.6 ± 0.7 | 3.3 ± 1.2 | 2.3 ± 1.3 | 1.8 ± 1.9 | .05 |
| Insulinlike growth factor-I SDS | −2.1 ± 0.7 | −2.3 ± 0.5 | −2.3 ± 0.4 | −2.5 ± 0.3 | .24 |
| Growth hormone mean dose at 6 mo (mg/d) | … | 0.61 ± 0.3 | … | 0.67 ± 0.3 | .66 |
| History of irradiation, no. (%) | 6 (75) | 7 (78) | 10 (53) | 10 (53) | .40 |
| Time since irradiation (mo) | 141.4 ± 91 | 132.5 ± 118 | 87.2 ± 104 | 62.6 ± 101 | .24 |
| Hypoadrenalism, no. (%) | 3 (38) | 4 (44) | 7 (37) | 14 (74) | .11 |
| Hypothyroidism, no. (%) | 7 (88) | 8 (89) | 13 (68) | 16 (84) | .62 |
| Hypogonadism, no. (%) | 7 (88) | 8 (100)b | 12 (63) | 12 (63) | .16 |
| Diabetes insipidus, no. (%) | 4 (50) | 1 (11) | 5 (26) | 6 (32) | .41 |
| Pituitary hormone defciencies, no. (%)c | |||||
| 0 | 1 (12) | 0 (0) | 4 (21) | 1 (5) | .29 |
| 1 | 0 (0) | 1 (11) | 4 (21) | 3 (16) | .72 |
| 2 | 3 (38) | 3 (33) | 2 (11) | 5 (26) | .33 |
| 3 | 1 (12) | 4 (44) | 7 (37) | 5 (26) | .50 |
| 4 | 3 (38) | 4 (44) | 2 (11) | 5 (26) | .18 |
| Current tobacco use, no. (%) | 2 (25) | 0 (0) | 1 (5) | 4 (21) | .23 |
| Estrogen use, no. (%) | 5 (62) | 5 (56) | 8 (42) | 9 (47) | .81 |
| Antidepressant use, no. (%) | 2 (25) | 1 (11) | 5 (26) | 8 (42) | .42 |
| Previous transsphenoidal surgery, no. (%) | 8 (100) | 8 (89) | 15 (79) | 17 (89) | .73 |
| Time since surgery (mo) | 148 ± 83 | 104 ± 80 | 126 ± 103 | 125 ± 117 | .87 |
| Time since cure of acromegaly (mo) | 95 ± 97 | 56 ± 53 | … | … | .34 |
| Quality of Life-AGHDAd | 11.5 ± 5.7 | 10.0 ± 6.8 | 8.21 ± 6.2 | 9.2 ± 7.6 | .70 |
| Symptom Questionnaired | |||||
| Anxiety | 11.1 ± 5.4e | 6.4 ± 4.7 | 6.4 ± 5.3 | 2.5 ± 2.8e | .0037 |
| Depression | 9.9 ± 6.1 | 5.6 ± 6.4 | 4.2 ± 5.4 | 2.8 ± 3.4 | .053 |
| Anger or Hostility | 5.9 ± 4.6 | 3.8 ± 6.4 | 2.6 ± 4.3 | 1.8 ± 2.4 | .26 |
| Somatic Symptoms | 10.4 ± 6.9 | 8.8 ± 4.0 | 8.2 ± 5.7 | 6.3 ± 4.7 | .45 |
| 36-Item Short-Form Health Surveyf | |||||
| Physical Functioning | 63.8 ± 21.3 | 80.6 ± 15.8 | 79.4 ± 19.3 | 68.1 ± 29.7 | .24 |
| Role Limitations due to Physical Health | 68.8 ± 39.5 | 58.3 ± 41.5 | 77.8 ± 34.2 | 56.3 ± 41.3 | .39 |
| Bodily Pain | 63.1 ± 38.1 | 76.4 ± 20.2 | 71.0 ± 26.5 | 75.2 ± 21.9 | .70 |
| General Health Perception | 38.8 ± 22.8 | 61.7 ± 16.6 | 59.4 ± 23.4 | 50.9 ± 24.0 | .12 |
| Energy or Fatigue | 26.9 ± 19.8 | 28.9 ± 20.3 | 45.6 ± 21.1 | 38.8 ± 24.7 | .14 |
| Social Functioning | 65.6 ± 12.9 | 70.8 ± 26.5 | 81.3 ± 24.7 | 75.8 ± 26.8 | .46 |
| Role Limitations due to Emotional Health | 62.5 ± 37.5 | 77.8 ± 37.3 | 88.9 ± 16.2 | 81.2 ± 27.1 | .18 |
| Emotional Well-Being | 55.0 ± 23.5e | 65.3 ± 20.0 | 74.4 ± 11.1 | 75.5 ± 13.0e | .02 |
Abbreviations: AGHDA = Adult Growth Hormone deficiency Assessment; SDS = standard deviation score.
a
Data are presented as number (%) or mean ± standard deviation.
b
Data on hypogonadism were available for 8 subjects in this group.
c
Other than growth hormone deficiency.
d
Tests in which lower scores refect better quality of life.
e
These 2 groups in this subscale were signifcantly different.
f
Test in which higher scores refect better quality of life.